New research suggests that patients who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt conventional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such drugs need to be aware of the risk of rapid rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting weight within about one and a half years.
Weighing Therapies
The study, which looked at dozens of trials involving thousands of patients, compared the effects of the injectable medications with conventional dieting.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually have a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors propose the way of the jabs explains the amplified regain.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is no longer kept in check, making overeating much more probable."
A Chronic Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals contend that, given the significant potential of weight regain, the therapy is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," akin to managing diseases like diabetes.
User Experiences
People who have stopped the medication describe a powerful return of hunger.
"It was like a trigger flipping and I was suddenly ravenous," described an individual.
This challenge is worsened if patients have not established permanent dietary or behavioural modifications during treatment.
Significant Adoption
Figures show that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on ongoing behavioural changes.
